- Bevacizumab plus sorafenib fails to achieve clinical benefit threshold in patients with heavily pretreated ovarian cancer.
- Clinical activity was observed in bevacizumab-naive patients.
- Baseline low plasma IL-8 levels were associated with clinical benefit.
Why this matters
- Patients with recurrent ovarian cancer have poor prognosis.
- Phase 2 study of 54 heavily treated patients (41 bevacizumab-naive and 13 bevacizumab-prior) with ovarian cancer treated with bevacizumab+sorafenib.
- Funding: National Cancer Institute.
- In 35 evaluable bevacizumab-naive patients:
- Overall clinical benefit rate was 77%.
- 9 patients achieved partial responses, and 18 had stable disease ≥4 months.
- The overall median PFS was 5.5 (95% CI, 4.0-6.8) months.
- In the bevacizumab-prior group:
- No responses were observed.
- 54% of patients had SD ≥4 months.
- Median PFS was 4.0 (95% CI, 2.0-6.4) months.
- All grade 3/4 toxicities were seen in bevacizumab-naive patients.
- The most common treatment-related grade 3/4 adverse events were hypertension (31%) and venous thrombosis or pulmonary embolism (9%).
- Baseline low IL-8 concentration was associated with PFS ≥4 months (median, 12.88 vs 21.26 ng/mL; P=.031).
- Open-label, single-group.